Gitnux/Report 2026

Biologics Industry Statistics

The global biologics market reached $626.2 billion in 2025, explore the figures behind its $691.1B 2026 estimate, companies and trends.
225Statistics
98Sources
12Sections
1Visuals
42mRead
Biologics Industry Statistics
Samuel NorbergWritten by Samuel Norberg·Fact-checked by Maya Johansson
Published
How this report is researched
01Editorial Scope

An editor sets the topic, the inclusion criteria, and the evaluation framework before research starts.

02Source Research

AI search agents locate sources and extract each figure together with the document it came from.

Read our full methodology →

Search agents attach provenance to every extracted figure.

Next review: within 31 days

01 Industry overview

The biologics industry at a glance

The global biologics market reached $626.2 billion in 2025 and is estimated at $691.1 billion in 2026, supported by oncology, autoimmune and genetic-disease therapies.

$691.1B[84]
Global market estimate, 2026
9.7%[84]
Forecast CAGR, 2026–2033
44.4%[84]
North America share, 2025
18[68]
FDA biosimilars approved, 2025
Market size
The global biologics market was valued at $626.2 billion in 2025 and is estimated to reach $691.1 billion in 2026. Grand View Research projects the market to reach $1.32 trillion by 2033.[84]
Forecast & CAGR
The market is forecast to grow at a 9.7% compound annual growth rate from 2026 to 2033, rising from an estimated $691.1 billion in 2026 to $1.32 trillion in 2033.[84]
Market share & regions
North America held the largest regional share at 44.4% of global biologics revenue in 2025, while the United States held the largest country-level share. In Europe, biologic medicines represented 44% of pharmaceutical value at list prices in the latest IQVIA measurement, including originator biologics and biosimilars.[84][54]
Segmentation
Monoclonal antibodies were the largest product segment, with 66.3% of 2025 revenue. By disease category, oncology accounted for 28.7%; by manufacturing model, in-house production represented 84.7%.[84]
Key players & concentration
The market includes large diversified biopharma companies and specialist biotechnology firms, but a single global concentration ratio was not identified in the sources reviewed. EY reported that 72 biotech companies generated more than $500 million in sales in 2025, indicating a substantial group of scaled competitors alongside smaller firms.[85]
Pricing
Biosimilars are increasing price competition in biologics. In the EU, biosimilars represented 5% of pharmaceutical value at list prices and grew at 11%, while biologic medicines overall represented 44% of value.[54]
Trends, drivers & challenges
Growth is being driven by oncology, autoimmune and genetic-disease treatments, personalized medicine and companion diagnostics. Key challenges include patent cliffs, pricing uncertainty and financing pressure; EY reported $68.5 billion raised by biopharma in 2025, up 11% from 2024.[84][85]
Consumer behavior & competition
Biologics represented nearly half of U.S. prescription-drug spending in the latest HHS analysis, despite lower prescription volume than small-molecule medicines. Competition is intensifying as biosimilar uptake expands; FDA approved 81 biosimilars for 20 reference products from 2015 through 2025.[56][68]
M&A
Biopharma M&A remained focused on adding late-stage and platform technologies. In 2026, AbbVie agreed to acquire Apogee Therapeutics for approximately $10.9 billion, while GSK agreed to acquire Nuvalent for $10.6 billion; both transactions targeted growth assets and pipeline diversification.[86]
Regulation
FDA’s CBER approved biological license applications throughout 2025, including products for congenital fibrinogen deficiency and Wiskott-Aldrich syndrome. Separately, FDA’s CDER approved 18 biosimilars in 2025, including four involving reference products that previously had no approved biosimilars.[68]
Latest news
The latest industry data indicate strong 2025 performance: biotech revenues reached $232 billion, 72 companies exceeded $500 million in sales, and biotech market capitalization rose 28.8% to $1.65 trillion. EY also reported that deals worth at least $5 billion represented 59% of biopharma deal spending.[85]

02 Ranking

Top 10 Companies in the Biologics Industry

The leading companies in the biologics industry, ranked on market impact, performance, momentum, innovation and brand popularity.

Updated November 11, 2026 · Next review December 11, 2026

Verdict

Eli Lilly and Company stands out for metabolic, immunology and neuroscience biologics because revenue rose to $65.2 billion in 2025, while Roche is the pick for biologic medicines and diagnostics since pharmaceuticals sales reached CHF47.7 billion in 2025.

Ranked by Overall score · How we score ↓

Editor's top 3 picks

Where to start, by need.

  1. #1 Overall · Leader in metabolic & immunology biologics

    Eli Lilly and Company

    US

    Ranked #1 · 9.9 · Metabolic & immunology biologics

    Why we picked it: Its Metabolic, immunology and neuroscience biologics business expanded revenue to $65.2 billion in 2025, supported by Mounjaro and Zepbound.

    See in ranking ↓Visit lilly.com ↗

  2. Leader in biologic medicines and diagnostics

    Roche

    CH

    Ranked #2 · 9.1 · Biologic medicines and diagnostics

    Why we picked it: It reports a large Biologic medicines and diagnostics footprint, with CHF47.7 billion pharmaceuticals sales in 2025.

    See in ranking ↓Visit roche.com ↗

  3. Leader in oncology and specialty biologics

    AstraZeneca

    GB

    Ranked #3 · 9.1 · Oncology and specialty biologics

    Why we picked it: Its oncology, respiratory and rare-disease biologics portfolio translated to $58.7 billion total revenue across global medicines in 2025.

    See in ranking ↓Visit astrazeneca.com ↗

Pick 1 is the #1 company overall. Picks 2 and 3 are the highest-ranked companies in the top 5 that add a new segment.

Full ranking

Sort by
Top 10 companies in the biologics industry, 2026 – Gitnux ranking
#CompanyOverall ↓Company snapshot
1

Eli Lilly and Company

Metabolic & immunology biologics · US

9.9
2

Roche

Biologic medicines and diagnostics · CH

9.1
3

AstraZeneca

Oncology and specialty biologics · GB

9.1
4

Amgen

Biosimilars and inflammatory biologics · US

9.0
5

Novo Nordisk

Diabetes & obesity biologics · DK

8.9
6

GSK

Vaccines, HIV and specialty biologics · GB

8.7
7

Sanofi

Immunology, rare disease and vaccines · FR

8.6
8

Merck

Oncology, vaccines and biologic therapies · US

8.6
9

Pfizer

Vaccines, antibodies and specialty biologics · US

8.4
10

Gilead Sciences

Virology, oncology and cell therapy biologics · US

8.2

How we score

  • Impact (30%): scale and weight in the market (revenue, market share, employees, market position).
  • Performance (20%): recent revenue growth and operating margin; an analyst assessment where a company does not publish them.
  • Momentum (20%): growth trajectory and future potential.
  • Innovation (15%): R&D intensity and how technologically advanced the company is.

Popularity (brand search demand, 15%) counts toward Overall but is not published as a column. Overall leaves out what is not known.

Scale Scores are shown on a 7–10 scale with one decimal; bars start at 7.0.

Cadence Recalculated when new figures are published; next review December 11, 2026.

Independence. Rankings are editorially independent. Scores, ranks, picks and the verdict follow the method above; no company can pay to change them.

Cite this ranking

APA

Samuel Norberg. (2026, November 11). Top 10 companies in the biologics industry. In Biologics Industry Statistics. Gitnux. https://gitnux.org/biologics-industry-statistics/#top-companies

report visual · Projection

U.S. original biologics license applications approved under section 351(a)

U.S. original biologics license applications approved under section 351(a) grew from 20 in 2020 to 22 in 2025.

20 count
Start
+1.92%
CAGR · 5y
22 count
Projected
20202025
source-verifiedfda.gov2025

04 Statistics

Technology & Innovation

AI adoption stays broad across pharma and biotech, with 74% reporting active AI usage in 2025. Digital and robotics adoption still shows a gap to regulated clinical or manufacturing scaling.

AI in the biologics industry

  • 74% of pharma and biotech respondents reported active AI usage in 2025, according to NVIDIA’s global healthcare and life sciences survey.[1]
  • 62% of surveyed biotechnology and pharmaceutical organizations using AI reported using it regularly across R&D, while 38% used it in targeted applications in 2025.[2]
  • Fewer than 10% of drugmakers were scaling AI for clinical or commercial manufacturing in 2026, while 74% were at least several years away from applying it to regulated production.[3]
  • 67% of large biopharma companies and 23% of small biopharma companies had adopted AI or machine learning in 2024, based on a survey of 300 U.S. and European biopharma professionals.[4]

Automation in the biologics industry

  • 83% of surveyed biopharma supply-chain leaders said a significant portion of their workforce needed upskilling or reskilling to support digital transformation involving automation and other technologies.[5]
  • Large biopharma companies reported using robotics and automation at twice the rate of small biopharma companies in a 2024 industry survey.[6]
  • Advanced robotics was classified as an adopted but mainly pilot-scale technology in the 2023 ISPE Pharma 4.0 survey of 418 pharmaceutical-industry respondents.[7]

Digital Transformation in the pharmaceuticals and biotech sector (sector benchmark)

  • 13% of clinical-research organizations surveyed reported a comprehensive AI-driven digital programme in 2024.[8]
  • 45% of pharmaceutical companies surveyed were pursuing digitalization as an innovation or technology in 2024.[9]
  • 15.1% of global pharmaceutical-industry survey respondents reported that Pharma 4.0 digital transformation had not started in 2023.[7]
  • 35% of clinical-research organizations surveyed were piloting digital technologies in 2024, up from 29% in 2019.[8]
  • 58.1% of global pharmaceutical-industry survey respondents were in the pilots or systematic-ongoing-actions stages of Pharma 4.0 adoption in 2023.[7]

Technology Adoption in the pharmaceuticals and biotech sector (sector benchmark)

  • 37% of small biopharma respondents reported that more than 60% of their R&D laboratory instruments had automated data capture in 2024.[6]
  • 70% of global biopharma respondents had adopted an R&D data platform in 2023.[10]
  • 59% of global biopharma respondents had adopted artificial intelligence or machine learning in 2023.[10]
  • 63% of global biopharma respondents had adopted robotics and automation in 2023.[10]
  • 55% of biopharma AI adopters reported using AI in process development in 2024.[4]

Cloud Computing in the pharmaceuticals and biotech sector (sector benchmark)

  • 23% of small biopharma respondents had adopted cloud-based scientific software or SaaS in 2024.[4]
  • 17% of large biopharma respondents had adopted cloud-based scientific software or SaaS in 2024.[4]
  • 77% of life-sciences commercial IT leaders reported investing primarily in cloud infrastructure in 2024.[11]
  • 49% of biopharma survey respondents reported using cloud computing to facilitate day-to-day work in 2021.[5]
  • 18% of global biopharma respondents had adopted cloud-based scientific software or SaaS in 2023.[10]

Big Data in the pharmaceuticals and biotech sector (sector benchmark)

  • 43% of small and midsize pharmaceutical companies surveyed were pursuing big data and analytics in 2024.[9]
  • 48% of pharmaceutical companies surveyed were pursuing big data and analytics in 2024.[9]
  • 49% of clinical-research survey respondents reported using AI and big-data analytics in drug development in 2024.[8]
  • 55% of large pharmaceutical companies surveyed were pursuing big data and analytics in 2024.[9]
  • 33% of biopharma survey respondents reported using data lakes in day-to-day operations in 2021.[5]
  • 68% of pharmaceutical companies surveyed planned to use advanced analytics in 2024.[12]

IoT in the pharmaceuticals and biotech sector (sector benchmark)

  • 22.3% of IoT-using SMEs in the European healthcare industrial ecosystem applied IoT to energy-saving devices in 2023.[13]
  • 20.4% of SMEs in the European healthcare industrial ecosystem had adopted Internet of Things technologies in 2023, according to an industry survey.[13]

05 Statistics

Data & Analytics

Data readiness constraints dominate near-term execution. Across 116 commercial biopharma leaders, 96% said their data was not well-structured or AI-ready for scaling in 2025.

Business intelligence in the biologics industry

  • 70% of biopharma respondents had adopted an R&D data platform in 2023, including 79% of respondents at larger companies.[10]
  • 54% of biopharma respondents used a custom-built R&D data platform in 2023, while 45% used Amazon Web Services and 42% used Microsoft Azure.[10]
  • 37% of biopharma organizations qualified as data frontrunners in a 2025 survey of pharmaceutical and biotechnology executives.[14]

Data analytics in the biologics industry

  • More than half of surveyed pharmaceutical and biotechnology organizations were integrating real-world data with artificial-intelligence tools in 2024.[15]
  • 96% of surveyed biopharma companies considered real-world data and real-world evidence essential to organizational strategy in 2025.[5]
  • 75% of surveyed pharmaceutical and biotechnology organizations were already using real-world data in drug development, according to a 2024 industry survey.[15]
  • 80% of surveyed pharmaceutical and biotechnology respondents rated data analytics and data science among the highest-value AI workloads in 2025.[1]

Data Quality in the pharmaceuticals and biotech sector (sector benchmark)

  • Across 500 pharmaceutical and biotechnology executives globally, 44% said their organization was prepared on data quality and completeness in 2025.[14]
  • Across 125 senior U.S. life-sciences leaders, 81% said accuracy and confidence in data were critical components of AI success in biopharma in 2026.[16]
  • Across 116 commercial biopharma leaders in the United States, Europe and Asia-Pacific, 96% said their data was not well-structured or AI-ready for scaling in 2025.[16]
  • Across 116 commercial biopharma leaders in the United States, Europe and Asia-Pacific, 81% identified data quality as their top data issue for the next 12 months in 2025.[16]
  • Across 116 commercial biopharma leaders in the United States, Europe and Asia-Pacific, 73% reported significant data quality issues in 2025.[16]

Data Governance in the pharmaceuticals and biotech sector (sector benchmark)

  • Across 200 global life-sciences R&D respondents, 46% called for templates for standardization and metadata to make data FAIR at scale in 2024.[17]
  • Across 11 pharmaceutical regulatory organizations, 9% reported a comprehensive approach to onboarding standards such as IDMP and XEVMPD, with regular source qualification, connected systems and data cleaning in 2023.[18]
  • Across 200 global life-sciences R&D respondents, 51% identified maintenance and management of data standards and ontologies as a key FAIR-data need in 2024.[17]
  • Across 500 pharmaceutical and biotechnology executives globally, 54% said their organization was prepared on data governance in 2025.[14]
  • Across 200 global life-sciences R&D respondents, 49% called for more data-governance frameworks to make data FAIR at scale in 2024.[17]

KPIs in the biologics industry

  • 72% of surveyed life-sciences companies spent up to 100 days per year matching healthcare-professional data across different sources in 2025.[19]
  • 35% of surveyed top biopharma executives described their organizations as connected, using integrated historical and real-time data with AI for process optimization and decision-making in 2025.[20]

06 Statistics

Strategy & Growth

Contract development and manufacturing remains a core demand lever, with $20.7 billion in global biologics CDM market value in 2024 after 11% growth from 2023.

Growth in the biologics industry

  • 37% was year-over-year growth in the advanced-therapies segment of the global biologics contract-manufacturing market in 2024.[21]
  • $20.7 billion was the global biologics contract-development-and-manufacturing market in 2024, after 11% growth from 2023.[21]
  • 9.6% was WuXi Biologics revenue growth from 2023 to 2024, reaching approximately RMB18.68 billion.[22]
  • $3.7 billion was the 2024 global advanced-therapies contract-manufacturing market value.[21]
  • 66% of global biologics contract-manufacturing market value came from protein-based biologics in 2024.[21]

Differentiation in the biologics industry

  • 51% of global biologics contract-manufacturing revenue was captured by the eight largest CDMOs in 2024.[21]
  • 80% of global biologics contract-manufacturing market value was controlled by large and mid-sized providers in 2024.[21]
  • 18% of global biologics contract-manufacturing market value came from advanced therapies in 2024.[21]

Mergers and acquisitions in the biologics industry

  • $267 million was the fair value of AstraZeneca’s 2024 acquisition of cell-therapy company Gracell.[23]
  • $427 million was the cash payment in Novartis’s 2024 acquisition of Kate Therapeutics, excluding potential milestone payments.[23]
  • $1.9 billion was the settlement payment for Novartis’s acquisition of MorphoSys, which closed in May 2024.[23]
  • $800 million was the approximate net consideration for Johnson & Johnson’s acquisition of bispecific-antibody company Proteologix in 2024.[23]
  • $518 million was the fair value of Novartis’s acquisition of gene-therapy company Kate Therapeutics in 2024.[23]

07 Statistics

People & Workforce

Biologics operations lean into hiring and reskilling as digital transformation progresses, with 64% of surveyed biopharma organizations recruiting for 2026.

Hiring in the biologics industry

  • 64% of surveyed biopharma organizations were actively recruiting for 2026, and 41% expected their number of open roles to increase.[24]
  • Life-sciences job postings for data engineers increased 69% between 2019 and 2024, according to Deloitte labor-market analysis.[5]
  • 58% of R&D professionals who changed jobs moved to a pharmaceutical company, according to analysis of life-sciences talent movements.[25]
  • Life-sciences job postings for data scientists increased 16% between 2019 and 2024, according to Deloitte labor-market analysis.[5]

Employee retention in the biologics industry

  • 58% of R&D professionals who changed jobs moved to a pharmaceutical company, indicating substantial mobility within the biopharma talent market.[25]
  • 8.7% was the estimated average employee turnover rate reported by biopharma employers for 2025, with a median rate of 8%.[24]

Remote Work in the pharmaceuticals and biotech sector (sector benchmark)

  • Across U.S. chemical and pharmaceutical manufacturers, 5.7% of positions were fully remote in the 2024 hiring outlook survey.[26]
  • Among life-sciences companies with remote-work options, 50.0% cited competition with technology and other industries as a reason for their policy in 2023.[27]
  • Across U.S. life sciences companies, 65.9% reported implementing, expanding, or considering remote-work options for at least some employees in 2023.[27]
  • Among privately held life-sciences companies surveyed, 21.7% had some portion of their workforce fully remote in 2025.[28]

Hybrid Work in the pharmaceuticals and biotech sector (sector benchmark)

  • Among surveyed life-sciences companies in the MassBio Human Resources Roundtable, 97% planned to implement hybrid work models for the long term in 2022.[29]
  • Among surveyed life-sciences employers in the BioHealth Capital Region, 60% expected at least a hybrid workforce after the pandemic in 2021.[30]
  • Across U.S. chemical and pharmaceutical manufacturers, 44.5% of positions were fully hybrid in the 2024 hiring outlook survey.[26]
  • Among life-sciences CEOs, 83% expected corporate employees whose roles were traditionally office-based to work in a hybrid environment three years after the 2024 survey.[31]

Upskilling in the biologics industry

  • 8% lower tool-use frequency was associated with researchers reporting insufficient training resources in a 2024 study of researchers using generative AI at work.[32]
  • 83% of surveyed biopharma supply-chain leaders said a significant portion of their workforce needed upskilling or reskilling for digital transformation.[5]
  • AI-skill availability among life-sciences R&D professionals increased 26% from 2023 to 2024, compared with 15% growth in the overall talent pool.[25]

Employee Engagement in the pharmaceuticals and biotech sector (sector benchmark)

  • At Amneal Pharmaceuticals, global employee engagement reached 88% in the company’s 2024 reporting year.[33]
  • Across the Culture Amp pharmaceuticals benchmark, 17% of employees disagreed that they had seen positive changes based on recent employee survey results in July 2026.[34]
  • Across the Culture Amp pharmaceuticals benchmark, 91% of employees agreed they understood how their work contributed to company goals in July 2026.[34]
  • Across the Culture Amp pharmaceuticals benchmark, 18% of employees were thinking of or actively seeking another job in July 2026.[34]

DEI in the biologics industry

  • 47% of surveyed biotechnology companies expected DEI efforts to enable business strategy five years into the future.[35]
  • 14% of workers at 81 responding Boston-area biotechnology companies were people of color excluding Asian employees, according to MassBio’s DEI survey.[36]
  • More than 80% of surveyed biotechnology companies rated DEI as an important area of strategic focus in 2024.[35]

Change Management in the pharmaceuticals and biotech sector (sector benchmark)

  • Across pharmaceutical-company respondents, organizations spent almost 14 months planning and initiating clinical-trial innovations before later evaluation, adoption, and implementation stages in 2022.[37]
  • Across 612 pharmaceutical-company respondents, clinical-trial innovations took an average of 69 months from planning to portfolio-wide implementation, excluding decentralized-trial adoption during COVID-19.[37]
  • Among pharmaceutical and biotechnology executives surveyed, 67% said their companies were using mergers and acquisitions to access talent or innovation in 2023.[38]
  • Among pharmaceutical and biotechnology executives surveyed, 26% expected to conduct a significant acquisition within the following 12 months in 2023.[38]
  • Among 125 pharmaceutical and biotechnology executives surveyed, 68% said their organizations were actively increasing investments in change management in 2023.[38]

08 Statistics

Customer & Sales

Customer experience in the biologics industry

  • 47% of pharma respondents identified improving customer experience as a top priority for the coming year in an EPG Health survey.[39]
  • The highest-performing pharmaceutical companies achieved a 26% Net Promoter Score among U.S. healthcare providers in 2025.[40]
  • Pharmaceutical companies averaged a negative 10% Net Promoter Score among more than 700 U.S. healthcare providers surveyed in 2025.[40]

Customer retention in the biologics industry

  • A 1.0-percentage-point reduction in drug switching was associated with manufacturer coupon use among 1,167,132 privately insured patients observed from 2017 to 2019.[41]
  • The probability of drug switching increased 40% after first coupon use and then declined by more than 50% after subsequent coupon use in the studied pharmaceutical markets.[41]

Customer acquisition in the biologics industry

  • Pharmaceutical manufacturer coupons reduced patient out-of-pocket spending by $45 on average in the studied sample.[41]
  • 1,167,132 privately insured patients who used at least one manufacturer coupon were included in a study of pharmaceutical customer acquisition and retention from 2017 to 2019.[41]

Customer loyalty in the biologics industry

  • 57% of Millennials said they were less likely to remain loyal to a brand when its online experience was not as easy or enjoyable as the in-person experience.[42]
  • 51% of consumers said they were less likely to remain loyal to a pharmaceutical brand when its online experience was not as easy or enjoyable as the in-person experience.[42]
  • 69% of Generation Z consumers said they were less likely to remain loyal to a brand when its online experience was not as easy or enjoyable as the in-person experience.[42]

09 Statistics

Marketing & Brand

Personalization and oncology focus drive marketing measurement, and 47% of respondents in late-2025 surveys represented oncology, the largest therapeutic-area segment.

Marketing in the biologics industry

  • 63% of life-science drug-development-services companies tracked marketing return on investment in 2024, down from 66% in 2023.[43]
  • 81% of life-science drug-development-services companies had a clearly defined value proposition in 2024, up from 77% in 2023.[43]
  • 40% of life-science drug-development-services companies developed an annual public-relations or communications plan in 2024.[43]
  • 81% of life-science drug-development-services companies developed an annual marketing plan in 2024, up from 77% in 2023.[43]

Digital marketing in the biologics industry

  • 77% of pharmaceutical marketers in a late-2025 survey said personalization was critical to their digital strategy.[44]
  • 60% of brand-side pharmaceutical marketers surveyed in late 2025 worked for companies with more than $10 billion in annual revenue.[45]

Branding in the biologics industry

  • 47% of respondents in the late-2025 pharmaceutical marketing survey represented oncology, the largest therapeutic-area segment.[45]
  • 75% of pharmaceutical marketing-survey respondents in late 2025 were director level or higher.[45]
  • 56% of pharmaceutical marketing-survey respondents in late 2025 worked in oncology and/or rare-disease marketing.[45]

Social media in the biologics industry

  • 34% was the pharmaceutical industry’s social-media digital-marketing skills score in the 2023 benchmark.[46]
  • 56% was pharmaceutical marketers’ confidence in their social-media capability in the 2023 benchmark.[46]

Influencer Marketing in the pharmaceuticals and biotech sector (sector benchmark)

  • 50% of healthcare and pharmaceutical marketers reported dedicated and growing budgets for creator or influencer marketing in 2026, globally.[47]
  • 50% of physicians in Europe, APAC and North America said healthcare influencer or KOL content had changed their prescribing choices in 2024.[48]
  • 4.5% of high-engagement prescription-drug promotion posts across Facebook, Instagram, TikTok and YouTube came from pharmaceutical companies in the United States in 2025.[49]
  • 29% of healthcare and pharmaceutical marketers reported dedicated but flat budgets for creator or influencer marketing in 2026, globally.[47]
  • 44% of physicians in Europe, APAC and North America said healthcare influencer or KOL content had changed their perception of a medication in 2024.[48]

10 Statistics

Operations & Execution

Manufacturing throughput and CDMO capacity constraints show up alongside automation outcomes, including a 2.4 grams per liter average commercial monoclonal-antibody production yield in the cited survey.

Process optimization in the biologics industry

  • 38% of upstream biomanufacturing respondents reported implementing automation with efficiency improvements.[50]
  • 2.4 grams per liter was the average commercial monoclonal-antibody production yield reported for biomanufacturing operations.[50]
  • 16% of upstream biomanufacturing respondents reported unforeseen difficulties after implementing automation.[50]
  • 10% of respondents at 20 biologics drug-substance manufacturing plants used advanced analytics regularly for improvement actions or real-time optimization.[25]

Operational efficiency in the biologics industry

  • 57% of biopharma executives increased CDMO use during the survey year to address manufacturing and operational needs.[12]
  • 2.85 grams per liter was the average late-stage clinical monoclonal-antibody production yield in the cited biomanufacturing survey.[50]
  • 2.4 grams per liter was the average commercial monoclonal-antibody production yield in the cited biomanufacturing survey.[50]
  • 61.7% was mammalian-cell-culture capacity utilization in the cited biomanufacturing survey, down from 76.4% in 2004.[50]

Quality management in the biologics industry

  • 38% of biopharma executives reported severe or critical shortages of workers for fast-growing modalities including cell and gene therapies, mRNA and antibody-drug conjugates.[12]
  • 66% of biopharma executives using CDMOs reported high satisfaction with CDMO availability.[12]
  • 72% of biopharma executives using CDMOs reported high satisfaction with CDMO quality performance.[12]
  • 70% of biopharma executives using CDMOs reported high satisfaction with CDMO speed.[12]

Supply chain in the biologics industry

  • 56% of biopharma executives agreed that domestic biologics manufacturing would increase significantly over the following three years.[12]
  • 49% of qualified respondents reported difficulty finding a CDMO with available mammalian-production capacity in 2026.[51]
  • 33% of biopharma supply-chain executives said their organization was attempting to completely transform its supply chain using digital technologies.[5]
  • 31% of surveyed executives reported that their country experienced shortages of other biologics at least once a year.[52]

Outsourcing / Offshoring in the pharmaceuticals and biotech sector (sector benchmark)

  • 40% of surveyed pharma and biotech CDMO decision-makers identified small-molecule API as the most outsourced product in July 2024.[53]
  • 41% of surveyed pharmaceutical and biotech R&D leaders increased their use of functional-service-provider outsourcing versus two years earlier in 2023.[9]
  • 67% of global biotech and pharma companies outsourced pharmacovigilance operations in 2024, according to an IQVIA industry report.[54]
  • 54% of global biotech and pharma companies outsourced regulatory activities in 2024, according to an IQVIA industry report.[54]
  • 74% of surveyed pharmaceutical and biotech R&D leaders ranked patient recruitment among the top five drug-development activities likely to be outsourced in 2023.[9]

11 Statistics

Finance & Pricing

Biosimilar entry continues to pressure pricing, with an average 36-month price reduction of 31% after biosimilar market entry using IQVIA invoice-price data.

Pricing strategy in the biologics industry

  • 40% was the assumed manufacturer price reduction under a Most Favored Nation scenario for physician-administered biologics.[55]
  • 13% to 42% was the reported range of 36-month price reductions after biosimilar market entry.[56]
  • 31% was the average 36-month price reduction after biosimilar market entry using IQVIA invoice-price data.[56]
  • 20% was the modeled manufacturer price reduction that increased hospital buy-and-bill margins for 20 major biologics to $4.84 billion.[57]

Cost reduction in the biologics industry

  • $564 million was the projected 2028 reduction in manufacturers’ R&D investment under a 40% price reduction for 20 major physician-administered biologics.[57]
  • 25% was the median cost of goods sold as a share of price for biosimilars in the cited antibody-therapeutics cost analysis.[57]
  • $282 million was the projected 2028 reduction in manufacturers’ R&D investment under a 20% price reduction for 20 major physician-administered biologics.[57]
  • 25% of sales revenue was the assumed manufacturer R&D reinvestment rate used to estimate the effect of biologic price reductions.[57]

Profitability in the biologics industry

  • 85.1% of biologics net spending during the study period came from noncompetitive biologics.[56]
  • 68.2% to 72.0% was manufacturers’ share of net spending on competitive biologics from 2020 to 2022.[56]
  • 23.3% to 27.5% was providers’ share of net spending on competitive biologics from 2020 to 2022.[56]
  • 77.4% to 80.0% was manufacturers’ share of net spending on noncompetitive biologics from 2020 to 2022.[56]

Financial planning in the biologics industry

  • 20.4% was domestic R&D spending as a percentage of domestic sales for PhRMA member companies in 2024.[58]
  • 43% was the biopharma median internal R&D investment as a percentage of commercial cash flow in the 2010–2025 industry analysis.[59]
  • 20.9% was total R&D spending as a percentage of total sales for PhRMA member companies in 2024.[58]
  • 70% was the biopharma median investment in R&D and business development as a percentage of commercial cash flow in the 2010–2025 industry analysis.[59]

12 Statistics

Product & Service

The pipeline remains large across development stages, with 23,875 drugs in the global biopharma R&D pipeline in 2025 and a forecast of 52.2% biologics in 2029.

Product development in the biologics industry

  • More than $168 billion in projected pipeline value was associated with new drug modalities in 2024, driven largely by antibody-drug conjugates and GLP-1 medicines.[60]
  • 11,422 preclinical biopharmaceutical programs were recorded globally in 2024, representing 60.1% of all development programs.[49]
  • 18,999 biopharmaceutical development programs were recorded globally in 2024, up 82.4% from 10,417 in 2015.[49]
  • Approximately 1% of compounds entering human trials ultimately generated a positive financial return in the analyzed biopharmaceutical industry data.[54]
  • 22,800 molecules were in the global pharmaceutical development pipeline from preclinical stage to launch in 2024, with biologics forecast to represent 52.2% in 2029.[61]

Product lifecycle in the biologics industry

  • By the end of 2023, the US FDA had approved 45 biosimilars referencing 14 biologic medicines.[62]
  • Biologics approved by the US FDA receive 12 years of guaranteed protection from biosimilar competition, compared with five years for new small-molecule drugs.[49]
  • Fewer than 10% of compounds entering development reached the market in the IQVIA analysis of medicines launched from 1991 through 2020.[54]

Value proposition in the biologics industry

  • Approximately 10% of medicines launched between 2016 and 2020 were estimated to generate a positive lifetime economic return after costs and taxes.[54]
  • 46% of all pharmaceutical expenditures were attributed to biologic medicines in the cited US specialty-drug spending analysis.[57]
  • $92,000 was the median annual cost of treatment for biologics in the United States, compared with $33,000 for small-molecule drugs, in the analyzed sample.[49]

13 Statistics

Sustainability & Ethics

Emissions reporting and targets vary widely, with 52% of companies reporting Scope 3 emissions in 2023 while Scope 3 accounted for 88% of reported sector emissions.

Sustainability in the biologics industry

  • More than half of the top biopharma companies were certified by My Green Lab in the 2023 assessment.[63]
  • 397 million tonnes of carbon-dioxide equivalent were emitted by the biotechnology and pharmaceutical sectors across Scopes 1, 2 and 3 in 2023.[64]
  • 31% of analyzed biotechnology and pharmaceutical companies had medium-term Scope 1 and 2 targets aligned with a 1.5°C pathway in the 2024 report.[64]
  • 36 companies representing 56% of biotechnology and pharmaceutical sector revenue had committed to the UN Race to Zero campaign in the 2024 report.[64]

ESG in the biologics industry

  • 52% of companies in the biotechnologies and pharmaceuticals sector reported Scope 3 emissions in 2023, accounting for 88% of reported sector emissions.[65]
  • 76% of companies in the biotechnologies and pharmaceuticals sector had waste-management plans in 2023, but only 12% had quantifiable waste-reduction targets.[65]
  • 15% of companies in the biotechnologies and pharmaceuticals sector disclosed water-discharge data in 2023.[65]
  • 50% of companies in the biotechnologies and pharmaceuticals sector reported the amount of waste generated in 2023.[65]

Ethics in the biologics industry

  • 149 audits of clinical-trial activities were conducted by Sanofi for its pharma and vaccines operations in 2025.[66]
  • 67% of biologic and drug products had public results for trials in patients within six months of FDA approval in the analyzed sample.[67]
  • 58% of biologic and drug products in the analyzed sample were compliant with the FDA Amendments Act reporting requirements.[67]
  • 26% of biologic and drug products had publicly available results for all clinical trials supporting FDA approval in the analyzed sample.[67]

CSR in the biologics industry

  • 79 publications resulted from Sanofi clinical-trial data shared through its data-sharing program in 2025.[66]
  • 807 scientific and medical papers sponsored or signed by Sanofi were included in PubMed in 2025.[66]
  • 260 Sanofi clinical trials had data shared in 2025 through the company’s clinical-data-sharing program.[66]

Carbon footprint in the biologics industry

  • The 25 largest biopharma companies reduced annual Scope 1 and 2 emissions by approximately 5.3% per year from 2015 through the period assessed in 2023.[63]
  • Biotechnology and pharmaceutical sector emissions totaled 259 million tonnes of carbon-dioxide equivalent from public companies and 138 million tonnes from private companies in 2023.[64]
  • Scope 3 emissions were 6.5 times Scope 1 and 2 emissions combined for private biotechnology and pharmaceutical companies in the 2024 assessment.[64]
  • Scope 3 emissions were 5.4 times Scope 1 and 2 emissions combined for public biotechnology and pharmaceutical companies in the 2024 assessment.[64]

15 Statistics

Globalization & Expansion

North America remains the largest biologics revenue region at 44.4% in 2025. Global biomanufacturing capacity totaled 6,692 thousand liters in 2024.

Globalization in the biologics industry

  • 55% of Biogen product revenue came from outside the United States in 2024.[80]
  • 6,692 thousand liters was total global biomanufacturing capacity in 2024, comprising 2,340 in North America, 2,467 in Europe and 1,885 in Asia.[31]
  • 57.3% of WuXi Biologics revenue came from North America in 2024.[22]
  • 23.1% of WuXi Biologics revenue came from Europe in 2024.[22]
  • 15.1% of WuXi Biologics revenue came from mainland China in 2024.[22]

Supplier management in the biologics industry

  • $15.00 billion in supplier sales came from mail, courier and express-parcel delivery services supporting the U.S. biopharmaceutical industry in 2022.[81]
  • $26.70 billion in supplier sales came from organic and inorganic chemical inputs for the U.S. biopharmaceutical industry in 2022.[81]
  • $24.92 billion in supplier sales came from insurance services supporting the U.S. biopharmaceutical industry in 2022.[81]
  • $30.49 billion in supplier sales came from software, computer services and internet services supporting the U.S. biopharmaceutical industry in 2022.[81]
  • $34.45 billion in supplier sales came from real-estate services supporting the U.S. biopharmaceutical industry in 2022.[81]

Distribution channels in the biologics industry

  • Nearly 4,900 orders per day were fulfilled by specialty distributors in 2024.[82]
  • 51% of limited or exclusive specialty-pharmacy networks included CVS Health pharmacies as of January 2025.[83]
  • 382 specialty drugs had manufacturer-defined limited or exclusive pharmacy networks as of January 2025.[83]
  • 97% of U.S. specialty-drug volume was handled by AmerisourceBergen, McKesson and Cardinal Health, including their subsidiaries, in Deloitte’s analysis.[5]
  • 51% of limited or exclusive specialty-pharmacy networks included Accredo as of January 2025.[83]

Key questions about the biologics industry

What is the current size of the global biologics market?
The global biologics market reached $626.2 billion in 2025 and is estimated at $691.1 billion in 2026.
How fast is the biologics market expected to grow?
The market is forecast to grow at a 9.7% compound annual growth rate from 2026 to 2033, rising from $691.1 billion in 2026 to $1.32 trillion in 2033.
Which companies lead the biologics industry?
Eli Lilly and Company stands out for metabolic, immunology and neuroscience biologics because revenue rose to $65.2 billion in 2025, while Roche is the pick for biologic medicines and diagnostics since pharmaceuticals sales reached CHF47.7 billion in 2025.
What technology shifts are most visible in biologics R&D and data work?
In 2025, 74% of respondents reported active AI usage in 2025, and 70% of biopharma respondents adopted an R&D data platform in 2023.
How does market structure shape competition in biologics?
Monoclonal antibodies remain the largest product segment at 66.3% of 2025 revenue, while FDA approved 18 biosimilars in 2025.
What does the market show about biosimilars and pricing pressure?
In the EU, biosimilars represented 5% of pharmaceutical value at list prices and grew at 11%, while FDA approved 81 biosimilars for 20 reference products from 2015 through 2025.
Reference

Cite This Report

This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.

APA
Samuel Norberg. (2026, November 11). Biologics Industry Statistics. Gitnux. https://gitnux.org/biologics-industry-statistics
MLA
Samuel Norberg. "Biologics Industry Statistics." Gitnux, 11 Nov 2026, https://gitnux.org/biologics-industry-statistics.
Chicago
Samuel Norberg. 2026. "Biologics Industry Statistics." Gitnux. https://gitnux.org/biologics-industry-statistics.

Sources & references

98 sources cited across this report

  1. nvidia.com
  2. downloads.ctfassets.net
  3. biospace.com
  4. test.benchling.com
  5. deloitte.com
  6. benchling.com
  7. ispe.org
  8. pmlive.com
  9. ppd.com
  10. techresearchinfo.com
  11. insights.indegene.com
  12. pharmamanufacturing.com
  13. monitor-industrial-ecosystems.ec.europa.eu
  14. capgemini.com
  15. emjreviews.com
  16. veeva.com
  17. pistoiaalliance.org
  18. resources.indegene.com
  19. pharmalive.com
  20. accenture.com
  21. alirahealth.com
  22. www1.hkexnews.hk
  23. sec.gov
  24. marketing.biospace.com
  25. mckinsey.com
  26. naceweb.org
  27. innovatebio.org
  28. jthelander.com
  29. massbio.org
  30. biobuzz.io
  31. assets.kpmg.com
  32. arxiv.org
  33. amneal.com
  34. cultureamp.com
  35. dev.bio.org
  36. axios.com
  37. acrpnet.org
  38. crowe.com
  39. pharmaphorum.com
  40. zs.com
  41. pubmed.ncbi.nlm.nih.gov
  42. pwc.com
  43. scorrmarketing.com
  44. solli.global
  45. health-union.com
  46. target-internet.s3.eu-west-2.amazonaws.com
  47. brand-news.it
  48. sermo.com
  49. jamanetwork.com
  50. bioprocessintl.com
  51. dhruv_cp.rodpub.com
  52. cdn.cytivalifesciences.com
  53. glginsights.com
  54. iqvia.com
  55. academic.oup.com
  56. aspe.hhs.gov
  57. pmc.ncbi.nlm.nih.gov
  58. cdn.aglty.io
  59. investor.regeneron.com
  60. bcg.com
  61. jmfl.com
  62. eprints.lse.ac.uk
  63. nature.com
  64. mygreenlab.org
  65. static.seitosei-presse.com
  66. dotcom.prod.accelerator.sanofi
  67. bmjopen.bmj.com
  68. fda.gov
  69. files.gao.gov
  70. middlemarketcenter.org
  71. acrohealth.org
  72. lifesciencesny.org
  73. fortinet.com
  74. cpl.thalesgroup.com
  75. kiteworks.com
  76. openpharma.blog
  77. etla.fi
  78. insights.economistenterprise.com
  79. abbvie.pr
  80. investors.biogen.com
  81. phrma.org
  82. chaindrugreview.com
  83. rxalmanac.com
  84. grandviewresearch.com
  85. ey.com
  86. biobucks.co
  87. investor.lilly.com
  88. roche.com
  89. astrazeneca.com
  90. investors.amgen.com
  91. annualreport.novonordisk.com
  92. gsk.com
  93. sanofi.com
  94. merck.com
  95. annualreview.pfizer.com
  96. gilead.com
  97. sciencedirect.com
  98. jpmorgan.com